Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Bioxcel Therapeutics Inc (BTAI)

Bioxcel Therapeutics Inc (BTAI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Bioxcel Therapeutics Inc 555 LONG WHARF DRIVE NEW HAVEN CT 06511 USA

www.bioxceltherapeutics.com Employees: 80 P: 475-238-6837

Sector:

Medical

Description:

BioXcel Therapeutics Inc. is a clinical stage biopharmaceutical company. It focuses on drug development which utilizes novel artificial intelligence to identify the next wave of medicines across neuroscience and immuno-oncology. The company's product portfolio include BXCL501, a sublingual thin film formulation of dexmedetomidine designed for acute treatment of agitation resulting from neurological and psychiatric disorders, and BXCL701, an immuno-oncology agent designed for treatment of a rare form of prostate cancer and for treatment of pancreatic cancer. BioXcel Therapeutics Inc. is based in the United States.

Key Statistics

Overview:

Market Capitalization, $K 45,706
Enterprise Value, $K 118,366
Shares Outstanding, K 21,869
Annual Sales, $ 2,270 K
Annual Net Income, $ -59,600 K
Last Quarter Sales, $ 100 K
Last Quarter Net Income, $ -30,910 K
EBIT, $ -50,670 K
EBITDA, $ -50,360 K
60-Month Beta 0.21
% of Insider Shareholders 3.70%
% of Institutional Shareholders 30.68%
Float, K 21,060
% Float 96.30%
Short Volume Ratio 0.38

Growth:

1-Year Return -66.13%
3-Year Return -99.24%
5-Year Return -99.70%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth 27.26%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -2.18 on 11/12/25
Next Earnings Date 11/13/25
Earnings Per Share ttm -9.70
EPS Growth vs. Prev Qtr 11.02%
EPS Growth vs. Prev Year 57.42%
Annual Dividend & Yield 0.00 (0.00%)
Annual Dividend & Yield (Fwd) 0.00 (0.00%)
Dividend Payout Ratio 0.00%
Most Recent Split 1-16 on 02/10/25

BTAI Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % 0.00%
Return-on-Assets % -185.00%
Profit Margin % -2,625.55%
Debt/Equity -1.23
Price/Sales 18.43
Price/Cash Flow N/A
Price/Book N/A
Book Value/Share -4.45
Interest Coverage -2.94
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar